Evaluation of long antigen exposition dendritic cell therapy (LANEX-DC®) in the adjuvant treatment of pancreatic cancer – results of a single center analysis
Archives of Cancer Science and Therapy · 2022
DOI: 10.29328/journal.acst.1001027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Cancer Science and Therapy, 2022. Verfasst von Gansauge Frank und 1 weiteren Autor:innen. Die Arbeit nennt 11 Literaturangaben.
Abstract (Originalsprache)
Introduction
Even after surgical resection and adjuvant chemotherapy in pancreatic cancer the 5-year disease-free survival times (DFS), as well as overall survival rates (OS), are still low and median survival times are below 2 years. Here we retrospectively analyzed the outcome of immunotherapy in the additional adjuvant treatment of pancreatic cancer with long antigen exposition dendritic cell therapy (LANEX-DC®) in 28 patients who were treated at our institution. Patients: Data were available from 28 patients. Dendritic cells (LAEX-DC®) were produced according to a recently published protocol.
Results
Therapy was well tolerated and no serious side effects were observed. The median disease-free survival times and the median survival times were 16,9 months and 29,4 months respectively. Five-year DFS and OS were 14,3% and 17,9%.
Conclusion
We were able to show in a small cohort of patients that additional treatment with dendritic cells (LANEX-DC®) is highly effective and extends the median disease-free survival times as well as the median survival in the adjuvant treatment of pancreatic cancer, whereas the five-year overall survival still remains unsatisfactory.
Zitieren
APA
Frank, G., & Bertram, P. (2022). Evaluation of long antigen exposition dendritic cell therapy (LANEX-DC®) in the adjuvant treatment of pancreatic cancer – results of a single center analysis. Archives of Cancer Science and Therapy. https://doi.org/10.29328/journal.acst.1001027
Vancouver
Frank G, Bertram P. Evaluation of long antigen exposition dendritic cell therapy (LANEX-DC®) in the adjuvant treatment of pancreatic cancer – results of a single center analysis. Archives of Cancer Science and Therapy. 2022. doi:10.29328/journal.acst.1001027
BibTeX
@article{Frank2022,
author = {Frank, Gansauge and Bertram, Poch},
title = {Evaluation of long antigen exposition dendritic cell therapy (LANEX-DC®) in the adjuvant treatment of pancreatic cancer – results of a single center analysis},
journal = {Archives of Cancer Science and Therapy},
year = {2022},
doi = {10.29328/journal.acst.1001027}
}
EUVIMED